{"url_path":"/sec/apre/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 ****Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1781983/0001104659-26-059734-index.html","accession_number":"0001104659-26-059734","cik":"0001781983","ticker":"APRE","issuer_name":"Aprea Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1781983/0001104659-26-059734-index.html","primary_entity_key":"0001781983","primary_entity_name":"Aprea Therapeutics, Inc."},"word_count":154,"has_tables":true,"body_markdown":"**Item 2.02****Results of Operations and Financial Condition.**\n\nOn May 13, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.\n\nIn accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.\n\n​"}